According to @StockMKTNewz, citing CNBC, Eli Lilly said its next-generation weekly weight-loss injection delivered what appears to be the highest weight loss observed so far in a late-stage trial and reduced knee arthritis pain (CNBC). CNBC reported that the therapy cleared the first of several upcoming studies, establishing a sequence of potential news catalysts traders can track for LLY (CNBC). The CNBC report, as summarized by @StockMKTNewz, did not address crypto markets, indicating no direct crypto linkage was mentioned in the source (CNBC).